(Q33311301)

English

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review (English)

1 reference

Europe PubMed Central

25 July 2017

0 references

rheumatoid arthritis

0 references

Robin Christensen

object named as

R Christensen

2

1 reference

ORCID Public Data File 2021

author name string

L E Kristensen

1

1 reference

Europe PubMed Central

25 July 2017

H Bliddal

3

1 reference

Europe PubMed Central

25 July 2017

P Geborek

4

1 reference

Europe PubMed Central

25 July 2017

B Danneskiold-Samsøe

5

1 reference

Europe PubMed Central

25 July 2017

T Saxne

6

1 reference

Europe PubMed Central

25 July 2017

publication date

1 November 2007

1 reference

Europe PubMed Central

25 July 2017

Scandinavian Journal of Rheumatology

1 reference

Europe PubMed Central

25 July 2017

36

1 reference

Europe PubMed Central

25 July 2017

6

1 reference

Europe PubMed Central

25 July 2017

411-417

1 reference

Europe PubMed Central

25 July 2017

North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Number needed to treat (NNT): estimation of a measure of clinical benefit

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Number needed to treat (NNT): implication in rheumatology clinical practice

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Simpson's paradox and calculation of number needed to treat from meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Meta-analysis, Simpson's paradox, and the number needed to treat

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Evidence based purchasing: understanding results of clinical trials and systematic reviews

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607067

21 January 2018

Identifiers

10.1080/03009740701607067

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33311301&oldid=1963103060"